bluebird bio, Inc. (NASDAQ:BLUE) – Analysts at Wedbush raised their FY2017 earnings per share (EPS) estimates for shares of bluebird bio in a research note issued to investors on Thursday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings of ($6.90) per share for the year, up from their prior forecast of ($6.94). Wedbush has a “Outperform” rating and a $174.00 price target on the stock. Wedbush also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.76) EPS, Q1 2018 earnings at ($1.68) EPS, Q2 2018 earnings at ($1.66) EPS, Q3 2018 earnings at ($1.73) EPS, Q4 2018 earnings at ($1.76) EPS, FY2018 earnings at ($6.82) EPS, FY2019 earnings at ($7.04) EPS, FY2020 earnings at ($4.32) EPS and FY2021 earnings at $5.70 EPS.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the previous year, the business earned ($2.07) EPS. The company’s revenue for the quarter was up 397.4% on a year-over-year basis. COPYRIGHT VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Expected to Post FY2017 Earnings of ($6.90) Per Share” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/bluebird-bio-inc-blue-expected-to-post-fy2017-earnings-of-6-90-per-share/1684847.html.

Other equities research analysts have also issued research reports about the stock. Sanford C. Bernstein began coverage on shares of bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 price target for the company. Cantor Fitzgerald reissued a “sell” rating and issued a $39.00 price target on shares of bluebird bio in a report on Monday, July 24th. BMO Capital Markets reissued a “buy” rating and issued a $108.00 price target on shares of bluebird bio in a report on Friday, August 4th. BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, Evercore ISI initiated coverage on shares of bluebird bio in a report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. bluebird bio presently has a consensus rating of “Buy” and a consensus target price of $131.05.

Shares of bluebird bio (BLUE) opened at $144.75 on Monday. bluebird bio has a one year low of $41.25 and a one year high of $164.80.

In other bluebird bio news, Director Daniel Lynch sold 500 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the transaction, the director now owns 3,300 shares in the company, valued at $396,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nick Leschly sold 25,667 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $115.18, for a total transaction of $2,956,325.06. Following the transaction, the insider now owns 339,368 shares of the company’s stock, valued at approximately $39,088,406.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 185,518 shares of company stock valued at $24,292,373. Corporate insiders own 3.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Comerica Bank bought a new stake in shares of bluebird bio in the 3rd quarter worth about $242,000. Bank of New York Mellon Corp lifted its holdings in shares of bluebird bio by 7.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 245,563 shares of the biotechnology company’s stock worth $33,729,000 after acquiring an additional 17,449 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of bluebird bio by 13.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 3,687 shares of the biotechnology company’s stock worth $506,000 after acquiring an additional 437 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of bluebird bio by 15.2% in the 3rd quarter. Rhumbline Advisers now owns 61,149 shares of the biotechnology company’s stock worth $8,399,000 after acquiring an additional 8,067 shares during the last quarter. Finally, Advisor Group Inc. lifted its holdings in shares of bluebird bio by 648.6% in the 3rd quarter. Advisor Group Inc. now owns 2,755 shares of the biotechnology company’s stock worth $378,000 after acquiring an additional 2,387 shares during the last quarter.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.